Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Feike Keli is a Traditional Chinese Medicine (TCM) granule formulation developed and manufactured by Taisheng Zhiyao. It is specifically indicated for pediatric patients suffering from cough and bronchitis associated with spleen and lung deficiency. The formulation is designed to strengthen the spleen, benefit qi, resolve phlegm, and suppress cough. Clinical symptoms addressed by this medication include excessive phlegm, shortness of breath, fatigue, and loss of appetite. The product is composed of several herbal ingredients, including Gizzard Lining (Jineijin), Mulberry Bark (Sangbaipi), Trichosanthes Peel (Gualoupi), Scutellaria (Huangqin), Arisaema with Bile (Dannanjing), Glehnia (Beishashen), Ophiopogon (Maidong), and Lycium Bark (Digupi). It is an approved and marketed pharmaceutical product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiao'er feike keli.